R2 IP

🎙️ The R² IP Podcast, hosted by Ray Miller, explores the intersection of law, science, and innovation. Ray is the US Chair of DLA Piper’s Life Sciences Patent Development & Strategy group and a trusted advisor to pharmaceutical, biotech, and technology companies. He has guided billion-dollar investments, extended patent exclusivity for portfolios valued at more than half a billion dollars, and built trade-secret programs strong enough to defeat high-stakes misappropriation claims. Each episode shows how intellectual capital—ideas, discoveries, and breakthroughs—can be transformed into intellectual property (IP) that protects, powers, and propels businesses forward. Ray’s work includes crafting regulatory exclusivity strategies where no composition-of-matter patents exist, securing freedom-to-operate for product launches, and navigating the International Trade Commission in complex infringement disputes—all experiences that bring a sharp, real-world perspective to every conver

R2 IP is a business podcast hosted by Raymond Miller, with 7 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Raymond Miller hosts R2 IP, a business show with 7 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #8

  Building a Biotech From Zero (Part 2 of 2): Investor Reality, Liquidity Myths & Founder Dynamics

  Nov 30, 202548 minS1

  In Part 2, Ray and David continue their deep dive into the realities of early-stage biotech growth—moving into warrant coverage, investor upside, dilution, and the often-overlooked truth that early equity can be illiquid for years. David breaks down liquidation waterfalls, down rounds, fiduciary duties, and what happens when a company approaches insolvency. They close with a candid look at managing founder relationships, avoiding “dead equity,” and keeping the company aligned when the science, money, and people all collide. 01:43 Understanding Conversion Discounts 02:07 Negotiation Points and Valuation 03:11 Enterprise Value and Share Price 04:37 Impact on Founders' Equity 08:47 Capital Gains Tax Benefits 13:47 Liquidity and Exit Strategies 19:07 Investor Motivations and Risks 34:20 Board and Management Obligations 43:11 Ray's Retreat Overview

  ListenShow Notes
• 

  Episode #7

  Building a Biotech From Zero (Part 1 of 2): Formation, Founders & First Money In

  Nov 26, 202531 minS1

  In Part 1 of this two-episode conversation, Ray sits down with longtime partner and life-sciences attorney David Smith to unpack the earliest—and most misunderstood—moments in forming a biotech company. They dive into choosing the right corporate structure, splitting founder equity, why timing matters, and how early financing tools like convertible notes and SAFEs really work. It’s a clear, practical look at the decisions that quietly determine whether a life sciences startup ever gets off the ground. It’s candid, practical, and full of the small details only 30 years of trenches-level experience can give you.

  ListenShow Notes
• 

  Episode #6

  Stacking Exclusivity: How Regulatory Incentives Power Drug Innovation

  Nov 5, 202543 minS1

  A pharmacist–turned–regulatory strategist and a 25-year patent attorney walk into a podcast… and blow up the myth that “no composition of matter means no value.” Ray and Nicole break down how regulatory exclusivity actually drives drug innovation, often more powerfully than patents. Hear how NCE, orphan drug, pediatric, and GAIN Act exclusivity can turn an old or overlooked molecule into a fundable, defensible asset. Discover why biologics play by completely different rules, why there’s no Orange Book, and what the mysterious “patent dance” really is. Learn how exclusivities can stack (and when they absolutely don’t), including real examples of companies turning five years into ten—or more. Get a preview of skinny labeling, the loophole that stops perpetual exclusivity and deserves its own episode. Plus: a rapid tour of EU, China, and Japan exclusivity systems and how global rights shape investment strategy. A fast, clear, myth-busting guide to one of the most misunderstood forces in the life sciences industry.

  ListenShow Notes
• 

  Episode #4

  Untangling Double Patenting with Robert Matthews

  Sep 17, 202538 minS1

  In this episode, Ray Miller welcomes longtime colleague and patent scholar Robert A. Matthews, Jr., author of the Annotated Patent Digest and one of the most respected voices in U.S. patent jurisprudence. Together, Ray and Bob dive deep into one of the thorniest doctrines in patent law: double patenting—both statutory and obviousness-type. They explore its roots in §101, how courts have shaped its modern application, and why it continues to frustrate practitioners and innovators alike. The discussion ranges from: The origins and evolution of double patenting doctrine. How obviousness-type double patenting (ODP) has become a frequent (and sometimes overused) tool by examiners. The impact of patent term adjustment (PTA) and patent term extension (PTE) on life sciences portfolios. Safe harbors under §121 and the importance of consonance. Practical strategies for navigating terminal disclaimers without giving away hard-fought patent term. Blending real-world strategy with academic perspective, this conversation offers a rare, behind-the-scenes look at how ODP disputes play out in prosecution, litigation, and policy. Whether you’re a litigator, prosecutor, or in-house counsel managing valuable life sciences IP, this episode provides sharp insights on how to safeguard term and preserve value.

  ListenShow Notes
• 

  Episode #3

  Radical Transparency or Regulatory Minefield? FDA’s CRL Data Dump Explained”

  Sep 2, 202527 minS1

  On July 10, 2025, the FDA did something unprecedented: it dropped over 200 Complete Response Letters (CRLs) for public viewing—documents once considered trade secret goldmines. In this episode, host Ray Miller (Partner, DLA Piper) dives deep into what this massive disclosure means for biopharma innovators, IP strategists, and investors. Is this bold new transparency a regulatory revolution—or a compliance nightmare? We unpack: Why CRLs are so sensitive—and why their release matters The collision course between radical transparency and trade secret law What this means for patent filings, investor communications, and litigation exposure How AI is helping lawyers and companies mine this data for insights and avoid costly missteps The future of hybrid IP strategies in the post-CRL publication world Whether you're a GC, VC, scientist, or simply regulatory-curious, this episode explores the fine line between disclosure and disaster—and how you can turn this shake-up into strategic advantage. R² IP: Where legal nuance meets biotech strategy—with just enough humor to make it go down smooth. https://www.raysretreat.com/s/Rays-Retreat-2025-Think-Piece-on-Radical-Transparency-FDAs-Complete-Response-Letter-Release-Challeng.pdf Radical Transparency: FDA’s Complete Response Letter Release Challenges Trade Secret Norms

  ListenShow Notes

Recent guests on R2 IP. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.